Key points from article :
In a groundbreaking study published in NPJ Aging, researchers from Emory University have discovered that psilocin — the active metabolite of psilocybin, the compound found in psychedelic mushrooms — can significantly delay aging in human cells and extend lifespan in mice. The research, led by Dr. Louise Hecker, found that psilocin extended the lifespan of human skin and lung cells by over 50% in laboratory conditions. In aged mice, a single low dose followed by monthly high doses over 10 months led to a 30% increase in survival, along with visible improvements in fur quality and hair regrowth.
Traditionally known for its use in mental health therapies, psilocybin appears to influence aging at a biological level by reducing oxidative stress, improving DNA repair, and preserving telomeres — the protective caps at the ends of chromosomes. These effects touch on several hallmarks of aging and could have broad implications for preventing age-related diseases such as cancer and neurodegeneration.
The study offers a potential new direction in longevity science, showing that even when administered later in life, psilocybin may lead not only to longer survival but also to healthier aging. Dr. Hecker, now at Baylor College of Medicine, notes that most body cells express serotonin receptors — the same receptors psilocybin targets — which may explain its widespread impact beyond the brain.
Dr. Ali John Zarrabi, co-investigator and director of psychedelic research at Emory, emphasized that this is about more than just extending life — it’s about improving quality of life in later years. With U.S. life expectancy lagging behind other nations, these findings suggest that psychedelic compounds like psilocybin could one day play a role in promoting longevity and well-being, especially if ongoing clinical trials succeed and FDA approval follows by 2027.
